News
Watch
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Commentary|Videos|October 15, 2025

Navigating Second-Line Treatment Decisions in Lower-Risk MDS

Author(s)Guillermo Garcia-Manero, MD

Fact checked by: Chris Ryan

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

Episodes in this series

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

EP. 1 Recent Shifts in the Management of Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.

EP. 2 OS Data From COMMANDS for Luspatercept in ESA-Naive, Lower-Risk MDS

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.

EP. 3 How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses the integration of luspatercept into real-world practice in ESA-naive, lower-risk MDS.

EP. 4 Integrating Luspatercept Into Clinical Practice and Community Settings in ESA-Naive Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

EP. 5 Navigating Second-Line Treatment Decisions in Lower-Risk MDS

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.

EP. 6 Key Areas of Ongoing Research in MDS

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Johannes Schetelig, MD, MSc

July 23rd, 2026

Data Unveil Surprising Survival Outcomes for Post-Transplant Cyclophosphamide vs ATLG as GVHD Prophylaxis

Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

July 16th, 2026

Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

Trending on OncLive

Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC

Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings

Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma

Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC

Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC